Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D07YHM
|
|||
| Former ID |
DIB003109
|
|||
| Drug Name |
LY-2456302
|
|||
| Synonyms |
Opioid receptor kappa (KOR) antagonist (alcohol dependence), Eli Lilly
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Alcohol dependence [ICD-11: 6C40.2; ICD-10: F10.2; ICD-9: 303] | Phase 2 | [1] | |
| Major depressive disorder [ICD-11: 6A70.3; ICD-10: F32.2] | Phase 2 | [1] | ||
| Company |
Eli Lilly & Co
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C26H27FN2O2
|
|||
| Canonical SMILES |
CC1=CC(=CC(=C1)C2CCCN2CC3=CC=C(C=C3)OC4=C(C=C(C=C4)C(=O)N)F)C
|
|||
| InChI |
1S/C26H27FN2O2/c1-17-12-18(2)14-21(13-17)24-4-3-11-29(24)16-19-5-8-22(9-6-19)31-25-10-7-20(26(28)30)15-23(25)27/h5-10,12-15,24H,3-4,11,16H2,1-2H3,(H2,28,30)/t24-/m0/s1
|
|||
| InChIKey |
ZHPMYDSXGRRERG-DEOSSOPVSA-N
|
|||
| CAS Number |
CAS 1174130-61-0
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Opioid receptor kappa (OPRK1) | Target Info | Antagonist | [2] |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | ||||
| Opioid prodynorphin pathway | ||||
| Reactome | Peptide ligand-binding receptors | |||
| G alpha (i) signalling events | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Peptide GPCRs | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders. Neuropharmacology. 2014 Feb;77:131-44. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.